Next-Generation Ocular Implants
PolyActiva’s pipeline of ocular implants with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy for eye care professionals treating patients with a wide range of ocular diseases.
IOP Reduction Without Daily Drops
- Fixed daily dose designed to provide consistent IOP reduction over 6 months
- Maximum compliance and adherence
Fully Biodegradable
- No implant persists beyond 4-6 weeks after treatment
- Additional implants can be safely administered near the end of therapy
Biocompatible
- Designed to be safe and well tolerated with no immune response, ocular inflammation, or toxicity
- Zero implant-related ocular adverse events
In-Office Procedure
- Rapid and minimally invasive administration in outpatient setting
- Administration integrates into clinical workflow and aligns with patient’s normal visit cycle
Reduce Risk of Post-Operative Infection
Fixed daily dose substitutes for peri-operative antibiotics and post-op drop therapy, maximizing compliance and adherence
Fully Biodegradable
No implant remains after 60 days
Biocompatible
Designed to be safe and well tolerated with no immune response, ocular inflammation, or toxicity
Streamlined Procedure
Rapid and minimally invasive administration integrated with cataract surgery
Latanoprost FA SR Ocular Implant
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension
Clinical Investigation Stage: Phase II
Micro implant.
Sustained drug release.
The Target Product Profile for the Latanoprost FA SR Ocular Implant, currently under development, aims to deliver the following clinical benefits:
IOP Reduction Without Daily Drops
- Fixed daily dose designed to provide consistent IOP reduction over 6 months
- Maximum compliance and adherence
Fully Biodegradable
- No implant persists beyond 4-6 weeks after treatment
- Additional implants can be safely administered near the end of therapy
Biocompatible
- Designed to be safe and well tolerated with no immune response, ocular inflammation, or toxicity
- Zero implant-related ocular adverse events
In-Office Procedure
- Rapid and minimally invasive administration in outpatient setting
- Administration integrates into clinical workflow and aligns with patient’s normal visit cycle
PolyActiva achieved study objectives in completed clinical study (NCT03604328) and interim analysis of ongoing study NCT04060758. The Latanoprost FA SR Ocular implant has not been approved by the U.S. Food and Drug Administration (FDA).
Levofloxacin Ocular Implant
Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery
Clinical Investigation Stage: Phase I
Micro implant.
Maximum infection
protection.
The Target Product Profile for the Levofloxacin Ocular Implant, currently under development, aims to deliver the following clinical benefits:
Reduce Risk of Post-Operative Infection
Fixed daily dose substitutes for peri-operative antibiotics and post-op drop therapy, maximizing compliance and adherence
Fully Biodegradable
No implant remains after 60 days
Biocompatible
Designed to be safe and well tolerated with no immune response, ocular inflammation, or toxicity
Streamlined Procedure
Rapid and minimally invasive administration integrated with cataract surgery
Early clinical studies (NCT04682288) conducted by PolyActiva have met clinical trial objectives.
The Levofloxacin Ocular implant has not been approved by the U.S. Food and Drug Administration (FDA)